NASDAQ:FBIO Fortress Biotech Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.87 +0.05 (+6.10%) (As of 06/29/2022 04:00 PM ET) Add Compare Share Today's Range$0.82▼$0.8850-Day Range$0.80▼$1.1452-Week Range$0.77▼$3.81Volume232,006 shsAverage Volume597,406 shsMarket Capitalization$93.45 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Stock Forecast (MarketRank)Overall MarketRank™2.19 out of 5 starsMedical Sector393rd out of 1,432 stocksPharmaceutical Preparations Industry166th out of 685 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Fortress Biotech has a forecasted upside of 1,164.4% from its current price of $0.87.Amount of Analyst CoverageFortress Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesFortress Biotech has received 315 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFortress Biotech has received 145 “underperform” votes. (Add your “underperform” vote.)Community SentimentFortress Biotech has received 68.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote “Outperform” if you believe FBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders26.30% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.92% of the stock of Fortress Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($0.77) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fortress Biotech (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.Read More FBIO Stock News HeadlinesJune 16, 2022 | finance.yahoo.comCheckpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell CarcinomaJune 12, 2022 | americanbankingnews.comFortress Biotech, Inc. (NASDAQ:FBIO) Given Average Recommendation of "Buy" by AnalystsJune 8, 2022 | finance.yahoo.comDo Institutions Own Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?June 6, 2022 | finance.yahoo.comCheckpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 31, 2022 | finance.yahoo.comFortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United StatesMay 23, 2022 | finance.yahoo.comJourney Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor ConferenceMay 19, 2022 | finance.yahoo.comCheckpoint Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceMay 19, 2022 | finance.yahoo.comMustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107May 18, 2022 | finance.yahoo.comFortress Biotech to Participate in Two Upcoming May 2022 Investor ConferencesMay 13, 2022 | finance.yahoo.comCheckpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory AgencyMay 13, 2022 | finance.yahoo.comFortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 10, 2022 | finance.yahoo.comJourney Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsMay 9, 2022 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue EstimatesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees173Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/30/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+1,164.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.860010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64.70 million Net Margins-88.31% Pretax Margin-231.44% Return on Equity-32.56% Return on Assets-17.58% Debt Debt-to-Equity Ratio0.46 Current Ratio3.31 Quick Ratio3.15 Sales & Book Value Annual Sales$68.79 million Price / Sales1.36 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.38Miscellaneous Outstanding Shares107,413,000Free Float79,163,000Market Cap$93.45 million OptionableOptionable Beta2.29 Fortress Biotech Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fortress Biotech stock. View analyst ratings for Fortress Biotech or view top-rated stocks. What is Fortress Biotech's stock price forecast for 2022? 5 brokers have issued twelve-month price targets for Fortress Biotech's stock. Their FBIO stock forecasts range from $6.00 to $20.00. On average, they expect Fortress Biotech's share price to reach $11.00 in the next year. This suggests a possible upside of 1,164.4% from the stock's current price. View analysts' price targets for Fortress Biotech or view top-rated stocks among Wall Street analysts. How has Fortress Biotech's stock price performed in 2022? Fortress Biotech's stock was trading at $2.50 at the start of the year. Since then, FBIO shares have decreased by 65.2% and is now trading at $0.87. View the best growth stocks for 2022 here. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Fortress Biotech. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.10. The biopharmaceutical company earned $23.93 million during the quarter, compared to the consensus estimate of $20.06 million. Fortress Biotech had a negative trailing twelve-month return on equity of 32.56% and a negative net margin of 88.31%. During the same period in the prior year, the firm posted ($0.11) earnings per share. View Fortress Biotech's earnings history. Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the following people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 67, Pay $92.65k)Mr. Michael S. Weiss Esq., Vice Chairman & Exec. Vice Chairman of Strategic Devel. (Age 56, Pay $92.65k)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 60, Pay $555.31k)Dr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 68, Pay $524.35k)Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of FBIO's competitors. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $0.87. How much money does Fortress Biotech make? Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $93.45 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64.70 million in net income (profit) each year or ($0.860010) on an earnings per share basis. How many employees does Fortress Biotech have? Fortress Biotech employs 173 workers across the globe. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for Fortress Biotech is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at [email protected], or via fax at 781-652-4545. This page (NASDAQ:FBIO) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
